Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
StemVacs-V iPSC
- Development stage
- Unknown
- Lead developer
- Therapeutic Solutions International
- Modality
- iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intradermal
01
Overview
StemVacs-V iPSC is an investigational **cell-based cancer vaccine** and **induced pluripotent stem cell derived therapy** developed by Therapeutic Solutions International and associated more recently with Res Nova Bio. The product is generated from a standardized induced pluripotent stem cell line differentiated into endothelial-like cells that resemble **tumor vasculature**, and it is engineered to express **alpha1,3-galactosyltransferase**, driving surface expression of **alpha-Gal** epitopes to enhance immunogenicity. The intended mechanism is active immunization against tumor blood-vessel antigens, thereby inducing immune attack on **tumor endothelial cells** and disrupting the vascular supply required for tumor growth. It has been described for development in metastatic breast cancer and also in glioma, colorectal cancer, and lung cancer, with provided context indicating **Phase II** clinical development in metastatic breast cancer.
- Other names
- second-generation StemVacs-V
02
Targets
α-Gal (Alpha-gal epitope)
Beyond the preview
Go deeper on StemVacs-V iPSC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on StemVacs-V iPSC.